Related Experiment Video
Updated: Aug 1, 2025

Repression of Multiple Myeloma Cell Growth In Vivo by Single-wall Carbon Nanotube SWCNT-delivered MALAT1 Antisense Oligos
Published on: December 13, 2018
Long non-coding RNA MAFG-AS1: A promising therapeutic target for human cancers
Zhiyu Huang1, Maoqing Zhang1, Jiayue Li1
1School of Pharmaceutical Sciences, Zhejiang Chinese Medical University, Hangzhou 310053, China.
Abstract:
Long non-coding RNAs (lncRNAs) are commonly known for their important characters in cancer progression. LncRNA MAFG-antisense 1 (AS1) (MAFG-AS1) has been discovered as a novel oncogenic lncRNA for several years. Accumulating data have demonstrated abnormal overexpression of MAFG-AS1 in various human cancers, including breast, bladder, liver, gastric, and lung. Importantly, through regulating various microRNAs and cell signaling pathways, MAFG-AS1 has been demonstrated to exhibit various biological effects, including proliferation, metastasis, and epithelial-mesenchymal transition (EMT). Meanwhile, abnormal overexpression of MAFG-AS1 is closely linked with histological grade, TNM stage, extensive depth of invasion, poor OS, and lymph node metastasis (LNM). In the present review, the authors summarized the previous studies on the biological properties, molecular mechanisms, and clinicopathological characters of MAFG-AS1 in human cancers. In summary, MAFG-AS1 is a promising prognostic biological marker and potential therapeutic target for cancer treatment.
Related Concept Videos
lncRNA - Long Non-coding RNAs
MicroRNAs
Experimental RNAi
Abnormal Proliferation
Non-LTR Retrotransposons
mTOR Signaling and Cancer Progression
The mTOR pathway or the...

